BANB Stock Analysis: Bachem Holding | SW
Biotechnology | SW, Switzerland | Market Cap: 5.639m CHF | 12M Return: 14.4% | CH0012530207 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.02M
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bachem Holding AG (SW: BANB) is a Swiss-based manufacturer of peptide active pharmaceutical ingredients (APIs), serving pharmaceutical and biotechnology customers across the research, clinical, and commercial stages of drug development. Beyond peptides, the company has expanded into oligonucleotide APIs and offers a broad services portfolio spanning project management, regulatory support, analytical work, GMP-grade production, and supply chain integration. Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem operates as a subsidiary of Ingro Finanz AG.
The company sits within the contract development and manufacturing (CDMO) segment of the pharmaceutical services industry, supplying both new chemical entities (NCEs) and generic peptide APIs to clients worldwide. Although classified under the GICS Materials sector and Commodity Chemicals sub-industry, Bachems business is more accurately described as a high-specialty cGMP manufacturer, operating in a niche where peptide-based therapies (such as GLP-1 agonists) and oligonucleotide drug candidates represent a growing share of pipeline development activity among large and emerging biopharma clients.
- GLP-1 obesity drug demand drives peptide API volume growth
- Capacity expansion at Bubendorf and Vista sites scales commercial revenue
- Asian peptide API competitors increase pricing pressure on margins
| Net Income: 149.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 4.20 > 1.0 |
| NWC/Revenue: 44.05% < 20% (prev 61.81%; Δ -17.76% < -1%) |
| CFO/TA 0.12 > 3% & CFO 289.9m > Net Income 149.0m |
| Net Debt (156.8m) to EBITDA (189.6m): 0.83 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.9m) vs 12m ago -0.52% < -2% |
| Gross Margin: 27.00% > 18% (prev 31.23%; Δ -4.22% > 0.5%) |
| Asset Turnover: 33.34% > 50% (prev 35.48%; Δ -2.14% > 0%) |
| Interest Coverage Ratio: 111.0 > 6 (EBIT TTM 137.5m / Interest Expense TTM 1.24m) |
| A: 0.13 (Total Current Assets 828.9m - Total Current Liabilities 516.8m) / Total Assets 2.34b |
| B: 0.40 (Retained Earnings 933.7m / Total Assets 2.34b) |
| C: 0.06 (EBIT TTM 137.5m / Avg Total Assets 2.12b) |
| D: 1.61 (Book Value of Equity 1.44b / Total Liabilities 895.4m) |
| Altman-Z'' = 4.30 = AA |
| DSRI: 0.96 (Receivables 184.0m/184.2m, Revenue 708.5m/677.9m) |
| GMI: 1.16 (GM 31.23% / 27.00%) |
| AQI: 1.16 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.05 (Revenue 708.5m / 677.9m) |
| TATA: -0.06 (NI 149.0m - CFO 289.9m) / TA 2.34b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at CHF 77.40 with a total of 70,080 shares traded. Over the past week, the price has changed by +2.86%, over one month by -0.39%, over three months by -0.83% and over the past year by +14.35%.
Current recommended Stop Loss: 73.10 (which is 5.6% or 1.4 ATR below the current price).
Bachem Holding has no consensus analysts rating.
P/E Trailing = 38.0051
P/E Forward = 33.2226
P/S = 7.9586
P/B = 3.8978
P/EG = 0.6112
Revenue TTM = 708.5m CHF
EBIT TTM = 137.5m CHF
EBITDA TTM = 189.6m CHF
Long Term Debt = 70.0k CHF (from longTermDebtTotal, last fiscal year)
Short Term Debt = 208.1m CHF (from shortTermDebt, last quarter)
Debt = 208.4m CHF (from shortLongTermDebtTotal, last quarter) + Leases 290k
Net Debt = 156.8m CHF (calculated: Debt 208.4m - CCE 51.6m)
Enterprise Value = 5.80b CHF (5.64b + Debt 208.4m - CCE 51.6m)
Interest Coverage Ratio = 111.0 (Ebit TTM 137.5m / Interest Expense TTM 1.24m)
EV/FCF = -122.3x (Enterprise Value 5.80b / FCF TTM -47.4m)
FCF Yield = -0.82% (FCF TTM -47.4m / Enterprise Value 5.80b)
FCF Margin = -6.69% (FCF TTM -47.4m / Revenue TTM 708.5m)
Net Margin = 21.02% (Net Income TTM 149.0m / Revenue TTM 708.5m)
Gross Margin = 27.00% ((Revenue TTM 708.5m - Cost of Revenue TTM 517.2m) / Revenue TTM)
Gross Margin QoQ = 25.01% (prev 28.70%)
Tobins Q-Ratio = 2.48 (Enterprise Value 5.80b / Total Assets 2.34b)
Interest Expense / Debt = 0.59% (Interest Expense 1.24m / Debt 208.4m)
Taxrate = 5.05% (7.92m / 156.9m)
NOPAT = 130.6m (EBIT 137.5m * (1 - 5.05%))
Current Ratio = 1.60 (Total Current Assets 828.9m / Total Current Liabilities 516.8m)
Debt / Equity = 0.14 (Debt 208.4m / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = 0.83 (Net Debt 156.8m / EBITDA 189.6m)
Debt / FCF = -3.31 (negative FCF - burning cash) (Net Debt 156.8m / FCF TTM -47.4m)
Total Stockholder Equity = 1.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.01% (Net Income 149.0m / Total Assets 2.34b)
RoE = 10.54% (Net Income TTM 149.0m / Total Stockholder Equity 1.41b)
RoCE = 9.73% (EBIT 137.5m / Capital Employed (Equity 1.41b + L.T.Debt 70.0k))
RoIC = 6.54% (NOPAT 130.6m / Invested Capital 1.99b)
WACC = 8.87% (E(5.64b)/V(5.85b) * Re(9.18%) + D(208.4m)/V(5.85b) * Rd(0.59%) * (1-Tc(0.05)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 75.84 | Cagr: 0.66%
[DCF] Fair Price = unknown (Cash Flow -47.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.74 | Revenue CAGR: 10.15% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.41 | Chg30d=+1.32% | Revisions=+25% | GrowthEPS=+21.9% | GrowthRev=+35.5%
EPS next Year (2027-12-31): EPS=3.04 | Chg30d=+1.42% | Revisions=+25% | GrowthEPS=+25.9% | GrowthRev=+23.8%
[Analyst] Revisions Ratio: +40% (up=2, down=0)